Similar articles

• A symposium on Attention Deficit Hyperactivity Disorder (ADHD). Four pertinent issues in treatment.

  Luk ES. Luk ES. Aust N Z J Psychiatry. 2002 Aug;36(4):479-81. doi: 10.1046/j.1440-1614.2002.t01-2-01065.x. Aust N Z J Psychiatry. 2002. PMID: 12169143 No abstract available.
• A symposium on Attention Deficit Hyperactivity Disorder (ADHD). 'Kid in the corner'.

  Hazell P. Hazell P. Aust N Z J Psychiatry. 2002 Aug;36(4):475-7. doi: 10.1046/j.1440-1614.2002.t01-5-01065.x. Aust N Z J Psychiatry. 2002. PMID: 12169141 No abstract available.
• Pemoline in ADHD.

  Winsberg B, Barbato M. Winsberg B, et al. J Am Acad Child Adolesc Psychiatry. 1997 Dec;36(12):1649-50. doi: 10.1097/00004583-199712000-00007. J Am Acad Child Adolesc Psychiatry. 1997. PMID: 9401321 Clinical Trial. No abstract available.
• Medications used in the treatment of disruptive behavior in children with FASD--a guide.

  Ozsarfati J, Koren G. Ozsarfati J, et al. J Popul Ther Clin Pharmacol. 2015;22(1):e59-67. Epub 2015 Feb 12. J Popul Ther Clin Pharmacol. 2015. PMID: 25715382 Review.
• [Pharmacotherapy of attention-deficit/hyperactivity disorder (ADHD) and comorbid disorders].

  Wiesegger G, Kienbacher C, Pellegrini E, Scheidinger H, Vesely C, Bangerl W, Friedrich M. Wiesegger G, et al. Neuropsychiatr. 2007;21(3):187-206. Neuropsychiatr. 2007. PMID: 17915180 Review. German.